(Morning News) Statistics from Johns Hopkins University shows that the cumulative cumulative crown diagnosis cases have exceeded 300 million.
The New York Times reported that the cumulative cumulative cases of crown diseases have reached 100 million after the epidemic out of the epidemic, which has reached more than 200 million in half a year, and reached 300 million in less than five months.This is because people in many countries include people in rich and poor countries, and they have not yet vaccinated the crown vaccine. One of the new variable strains shows that those who complete the vaccine may still be infected.
Although more and more experts believe that they should no longer pay attention to case data, some experts are worried that cases may still have a burden on the medical system.
Tan Desai, Director of the World Health Organization, pointed out that although the severe rate of severe illness caused by the infection of the Omikon variants seems to be lower than the Delta variants, it should not be classified as "mild" because it is because itLike other variety of strains, the infected patients are severely ill and died, so they cannot be taken lightly.
Although the number of cases is not the best barometer of the epidemic, it has always been a key indicator for measuring crown diseases. It is not only the benchmark for the government to relieve the epidemic measures, but also the benchmark for the people to try to understand the threat of the epidemic.
The effect of vaccine additional agent or decline in Modner benefited from repeating in vaccination worldwide
(Morning News) Stephane Bancel, executive president of Moderna, on Thursday (January in January (January)On the 6th) at a medical care conference hosted by Goldman Sachs, the efficacy of crown diseases may decline in the next few months, and people may need to inject additional additions in this fall.
Banser said at the association that Modner is studying a vaccine tailored for Omircor's variant virus, but this vaccine is unlikely to be available in the next two months.
Bancele said: "I still believe that we will need to add additional agents this year and later."
Modner has always benefited from repeating vaccines worldwide.The Group also stated in its third quarter earning report that by 2022, the US commercial additional market sales will be as high as US $ 2 billion (about S $ 2.7 billion).
Modner stocks have fallen 34.04 US dollars or 13.61 % over the past five trading days.The stock recovered slightly overnight, with a slightly $ 0.83 US dollars, and closed at 216.06 US dollars overnight.On December 30 last year, Bancele also sold 10,000 Modner stocks on his hand at the average price of $ 243.42 per share.
